Reaction of carbon monoxide with cystathionine β-synthase: implications on drug efficacies in cancer chemotherapy
被引:11
作者:
Kawahara, Brian
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95060 USAUniv Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95060 USA
Kawahara, Brian
[1
]
Sen, Suvajit
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USAUniv Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95060 USA
Sen, Suvajit
[2
]
Mascharak, Pradip K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95060 USAUniv Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95060 USA
Mascharak, Pradip K.
[1
]
机构:
[1] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95060 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA
Photo-activatable carbon monoxide (CO)-releasing molecules (photoCORMs), have recently provided help to identify the salutary effects of CO in human pathophysiology. Among them notable is the ability of CO to sensitize chemotherapeutic-resistant cancer cells. Findings from our group have shown CO to mitigate drug resistance in certain cancer cells by the inhibition of cystathionine beta -synthase (CBS), a key regulator of redox homeostasis in the cell. Diminution of the antioxidant capacity of cancer cells leads to sensitization to reactive oxygen species-producing drugs like doxorubicin and paclitaxel upon cotreatment with CO as well as in mitigating the drug effects of cisplatin. We hypothesize that the development of CO delivery techniques for coadministration with existing cancer treatment regimens may ultimately improve clinical outcomes in cancer therapy. Graphical abstract